AmpliTech Group heads into the aftermath of its Q1 2026 earnings release having delivered a revenue beat — and a week that has left short sellers caught between retreating positions and a price that has climbed 18.5% in five days.
The earnings print, released after the close on May 13, told two stories at once. Revenue came in at $5.35M, topping the $5.0M estimate and marking strong year-on-year top-line growth. The EPS line was a different matter — a $0.06 loss missed the $0.05 consensus by a penny. The stock rose roughly 1.9% in the immediate aftermath, a muted reaction that follows a similar pattern to the last confirmed print on April 9, when the stock fell 3.2% on the day before recovering 5.8% over the following five sessions. The March 30 event before that produced a 5.6% first-day gain. In short, AMPG's earnings reactions have been modest and short-lived in both directions.
The positioning picture going into the print was genuinely mixed. Short interest at 6.7% of free float is material for a micro-cap, but the direction of travel has been firmly lower. Shorts have cut their position by about 22% over the past month, and by a further 14% on a weekly basis — even as a single-day spike of 14% on May 12 showed that some sellers were re-entering around the $2.69 close. Borrow costs are low at 0.81%, down sharply from an April 13 spike above 4.6% that appears to have been an isolated event. Availability in the lending pool is moderate — with utilization at 47.5% against a 52-week peak of 54.3%, there is no meaningful squeeze pressure and plenty of capacity for new shorts if sentiment deteriorates. Options positioning offers little counterweight: the put/call ratio is running near the bottom of its recent range at 0.027, marginally below its 20-day average, suggesting the options market is not seeking downside protection at current levels.
The sole active analyst covering the stock — Maxim Group's Jack Vander Aarde — lowered his price target from $9 to $7 on March 30 while keeping a Buy rating, citing the same print that produced a 5.6% one-day gain. That target now sits at $7.00 against a stock trading at $2.69, implying considerable upside on the Street's only current view. The data-consistency note here: the gap between price and target is wide enough to flag. The target was set 44 days ago and may not yet reflect the Q1 miss on EPS. Valuation multiples in the dataset carry a 2022 timestamp and are not actionable for this note. The ORTEX short score of 56.5 is mid-range and has actually declined from a recent peak of 60.5 on May 6, consistent with the easing short interest trend rather than a build.
Institutional ownership adds a layer of context. Vanguard nearly doubled its position in Q1, adding over 1.15 million shares to reach 5.8% of the company. Bard Associates holds 6.3%. The founder and CEO, Fawad Maqbool, owns 10.7% outright and received a 50,000-share award in January alongside the CFO and COO — compensation grants rather than open-market purchases, but they signal that management compensation remains tied to the equity. Director Daniel Mazziota has been a consistent open-market buyer through 2025, accumulating shares at prices between $1.39 and $2.00. At $2.69, the stock now trades well above those entry points.
Peer performance provides an unflattering contrast. Among AMPG's closest correlated names, PRZO fell 21.5% on the week and OUST gave back 5.2%. ARBE managed a 6.1% gain, but the broader cohort underperformed AMPG's 18.5% weekly surge meaningfully. Whether the stock can hold those gains now that the earnings catalyst has passed — with EPS missing and no next event flagged — is the central question heading into the following week.
See the live data behind this article on ORTEX.
Open AMPG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
